OQROGet OQRO Pro
Politician trade (Senate)

Johnson & Johnson (JNJ)Sen. Thomas H Tuberville disclosed a sale $15K–$50K

Sen. Thomas H Tuberville disclosed a sale of Johnson & Johnson in the $15K–$50K range.

$15,001–$50,000
Reported range · official band, not an exact amount
17 days
Disclosure lag
Traded
Oct 29, 2024
Disclosed
Nov 15, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 10, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Sep 4, 2024CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  3. Sep 10, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Oct 29, 2024 · this disclosureCongressDisclosed sale of JNJ — reported range $15,001 - $50,000

What came next

  1. Nov 8, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Nov 22, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Nov 25, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Nov 26, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  5. Dec 6, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  6. Dec 10, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  7. Dec 12, 2024InsiderDirector purchased ~$147K of JNJ shares in the open market
  8. Dec 12, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  9. Dec 20, 2024FDARecall: PROLENE Polypropylene Suture, REF: EH7585H, 8706H, 8833H, 8963H, 8935H PROLENE Suture is indicated for use in general soft tissue approximation and/or ligation…
  10. Dec 23, 2024FDAFDA device clearance: INHANCE INTACT™
  11. Dec 24, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  12. Dec 31, 2024CongressDisclosed sale of JNJ — reported range $100,001 - $250,000
  13. Jan 5, 2025FDARecall: VARIPULSE Bi-Directional Ablation Catheter REF D141201. The Field Catheter is indicated for use in catheter based cardiac electrophysiological mapping (stimula…
  14. Jan 8, 2025Congress · 1 personMembers of Congress: 4 purchases
  15. Jan 12, 2025FDAFDA device clearance: Mentor™ CPX ™ 4 PLUS Enhance Breast Tissue Expander
  16. Jan 13, 2025FDAFDA device clearance: MENTOR™ MemoryShape™ Resterilizable Gel Breast Implant Sizer; MENTOR™ MemoryGel™ Resterilizable Gel Breast Implant Sizer; MENTOR™ MemoryGel™ Enhance Single Use…
  17. Jan 16, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  18. Jan 17, 2025FDAFDA drug approval: Spravato
  19. Jan 17, 2025FDAFDA device clearance: TriALTIS™ Spine System
  20. Jan 17, 2025FDAFDA device clearance: The ETHICON™ Total Energy System
View the official recordSenate eFD periodic transaction report

How to read Senate eFD periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 15 insider filings (SEC Form 4 or Form 144), 8 Congress trade reports, 167 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Sen. Thomas H Tuberville

The full history of Sen. Thomas H Tuberville is on the profile page.

How this filing works

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data